On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Semi Crushes Member in Decatur, Ill.
- Long-time Union Ally Mikie Sherrill Runs for New Jersey Governor
- FRA Suspends Safety Reports due to Government Shutdown
- SMART-TD to Port Terminal Railroad Association: Your Harassment Stops Now.
- Honoring the Professional Drivers Who Keep Our Children Safe
- Report Transit Assaults to Help SMART-TD Fight Back
- SMART, SMACNA cohost webinar on building success in residential HVAC
- Another RRB Office Moves to New Location
- Hunting accident claims life of Idaho member’s daughter
- Gardena City Council welcomes SMART-TD to represent GTrans Bus Operators